Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Here’s How AbbVie, JNJ May Turn Imbruvica into a $12 Billion Drug
Here’s How AbbVie, JNJ May Turn Imbruvica into a $12 Billion Drug
Here’s How AbbVie, JNJ May Turn Imbruvica into a $12 Billion Drug
Submitted by
admin
on December 7, 2015 - 10:37am
Source:
Bidness, ETC
News Tags:
AbbVie
JNJ
Imbruvica
chronic lymphocytic leukemia
Headline:
Here’s How AbbVie, JNJ May Turn Imbruvica into a $12 Billion Drug
Do Not Allow Advertisers to Use My Personal information
